Women's Health Diagnostic Test Market Moving Radiantly Toward 2021 by Growth Factors and Industry with Prominent Players by 2028 | Dickinson and Company, Siemens AG

According to the World Health Organization (WHO), around 570,000 women died due to breast cancer in 2015. Moreover, according to the Centers for Disease Control and Prevention (CDC), around 236,968 women were diagnosed with breast cancer, among which around 41,211 women died in 2014. The data indicates a growing prevalence of chronic diseases among women. Growing demand for early stage diagnosis of infection/diseases requires new rapid diagnostic tests and imaging systems which is expected to fuel growth of the women’s health diagnostic test market in the near future.

Initiatives taken by health organizations for prevention of chronic diseases and introduction of rapid diagnostic tests is expected to propel the market growth

In 2017, Naugatuck Valley Women’s Health Specialists (NVWHS) decided to form a free informational program for heart health with Boston Heart Diagnostics. The program would include treatment and diagnosis of cardiovascular diseases (CVD), and improving women’s heart health. This program is expected to create awareness of CVD related diseases among women.

In 2017, Mission Hope Cancer Center accredited by the National Accreditation Program for Breast Cancer Centers (NAPBC) joined Dignity Health Central Coast hospitals. In Mission Hope’s cancer care program. The breast cancer examination service and facility is expected to be provided to women. Moreover, in 2017, Dignity Health installed 3D imaging technology - Mammography in the central coast. This technology helps in detection of breast cancer before symptomatic stage, which increases 98% survival rate. Thus, this program is expected to create more awareness and early detection of cancer, which in turn is expected to augment the growth of women’s health diagnostic test market.

𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐚𝐭𝐞𝐫𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 – https://www.coherentmarketinsights.com/insight/request-sample/971

In 2016, Aeon Clinical Labs launched a RUO women’s health panel test, which is developed by Thermo Fischer Scientific. This test is based on PCR that detects 34 different target diseases including candidiasis, bacterial vaginosis, and sexually transmitted diseases such as gonorrhea, chlamydia, and some others. Aeon is further aiming to expand genetic assays for pharmacogenomics and hereditary cancer in the near future.

Some of the major factors hampering the market growth include high price of diagnostic imaging system and its related procedure.

Increasing prevalence of chronic diseases among women and rising awareness program is expected to fuel the growth of women’s health diagnostic test market

According to National Cancer Institute (NCI), in 2016, around 22,280 women were diagnosed with ovarian cancer and around 14,240 women succumbed to it in U.S. Furthermore, according to Cancer Research UK, in 2014, around 7,378 new cases of ovarian cancer, and around 55,222 cases of breast cancer were diagnosed in the U.K. Moreover, around 20 cases of ovarian cancers are diagnosed every day and are projected to increase by 15% in 2035.

Increasing incidence and prevalence of chronic diseases among women and demand for accurate and precise diagnostics are the major factors that are expected to augment the growth of the women’s health diagnostics market during the forecast period.

Organizations and foundations such as the National Breast Cancer foundation, World Health Organization, and National Institute of Health and Family Welfare (NIHFW) are conducting breast cancer awareness programs at local, state, and national levels, which is expected to fuel growth of the market during the forecast period.

Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2015, around 3,978,497 babies were born. This indicates an increase in pregnancy rates, which has generated demand for various gestation and fertility tests and treatments. Such factors are expected to propel growth of the women’s health diagnostic test market in the near future.

Some of the key players operating in the global women’s health diagnostic test market include Biomerieux SA, F. Hoffmann-LA Roche AG, Becton, Dickinson and Company, Siemens AG, Abbott Laboratories, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Inc., GE Healthcare, and Alere Inc.

𝐓𝐨 𝐠𝐚𝐢𝐧 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐨𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.coherentmarketinsights.com/insight/request-pdf/971

𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐖𝐨𝐦𝐞𝐧’𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐬𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

• In May 2019, Qiagen N.V. launched the first U.S. FDA-approved companion diagnostic test, Therascreen PIK3CA Kit, for identifying breast cancer.

• In January 2019, Nurx Inc. launched At-Home HPV Test Kits to detect the types of human papillomavirus (HPV) that are commonly found in cervical cancer.

• In September 2018, Mira, a part of Quanovate Tech Inc., launched Mira Fertility system personalized cycle prediction by measuring fertility hormone concentrations in urine samples. The devices also helps the women to know their fertility status.

• In December 2017, Inito, a medical technology start-up, launched a fertility monitor that helps women to track their ovulation days at home in an easy and convenient way. The single portable device uses smartphones to perform lab-grade medical diagnostic tests at home.

• In September 2017, GE Healthcare received U.S. FDA 510 (k) clearance for it’s first-ever mammography system. The device allows women to manage their own compression during the mammography exam with the help of company’s proprietary Senographe Pristina Dueta, a remote control.

𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐫 𝐐𝐮𝐞𝐫𝐲 𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐛𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠, 𝐕𝐢𝐬𝐢𝐭 𝐚𝐭 –
https://www.coherentmarketinsights.com/insight/talk-to-analyst/971

𝐖𝐨𝐦𝐞𝐧’𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐬𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐚𝐱𝐨𝐧𝐨𝐦𝐲:
By Application:

• Ovarian Cancer Test
o Diagnostic Imaging Tests
o Ovarian Cancer Tumor Marker Test
o Others

• Breast Cancer Test
o Biopsies
o Mammography
o Breast Cancer Tumor Marker Test
o Blood Chemistries and Blood Cell Count Test
o Others

• Osteoporosis Test
o Bone Densitometry
o In Vitro Blood Test
• Cervical Cancer Test
o PAP Smear
o HPV Test

• Pregnancy and Fertility Test
o Lab-Based Test
o Fertility Monitors
o Pregnancy Testing and Ovulation Prediction Kits

• Ultrasound Test
o Breast Imaging
o Obstetrics/ Gynecology Imaging

• Prenatal Genetic Screening and Carrier Test
o Cystic Fibrosis
o Torch Infections
o Down Syndrome and Edwards Syndrome
o Others

• Infectious Disease Test
o MRSA Test
o Hepatitis Test
o Tuberculosis Test
o Urinary Tract Infection Test
o Others

• Sexually Transmitted Disease (STD) Test
o HIV Test
o Chlamydia Trachomatis and Neisseria Gonorrhoeae Test
o Others

By End-use Industry:
• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

𝐓𝐨 𝐃𝐢𝐫𝐞𝐜𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 –https://www.coherentmarketinsights.com/insight/buy-now/971

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.